PUFA Salt Tablet Lubricants Without Dissolution Delay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Commonly used lubricants in pharmaceutical formulations, such as magnesium stearate, cause delays in tablet dissolution and adverse health effects, and existing alternatives do not adequately address these issues.
Innovation Solution
Using polyunsaturated fatty acid salts, particularly omega-3 and omega-6 fatty acid salts with basic amino acids or ions like magnesium and potassium, as lubricants in tablet formulations to achieve effective lubrication without the drawbacks of traditional lubricants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If magnesium stearate is used as a lubricant, then lubrication effectiveness is improved, but tablet dissolution is delayed
Solution Approach 1:
The patent changes the chemical composition parameter of the lubricant from traditional magnesium stearate to polyunsaturated fatty acid salts (such as sodium linoleate, potassium arachinate). This parameter change maintains lubrication effectiveness while eliminating the dissolution delay effect, as the polyunsaturated fatty acid salts do not form the same insoluble barrier on tablet surfaces as magnesium stearate.
Solution Approach 2:
The patent employs lubricants that are more readily degraded and eliminated from the body (polyunsaturated fatty acid salts) compared to persistent metallic salts. These alternative lubricants provide the necessary temporary lubrication during manufacturing but do not persist in the final product to interfere with dissolution or pose long-term health risks.
2Reliability
If traditional lubricants like stearic acid and magnesium stearate are used, then manufacturing reliability is improved, but adverse health effects occur
Solution Approach 1:
The patent converts potentially harmful saturated fatty acids into beneficial polyunsaturated fatty acid salts. These alternative lubricants not only maintain manufacturing reliability but also provide health benefits through their anti-inflammatory and cardiovascular protective properties, effectively turning a harmful substance category into a beneficial one.
Solution Approach 2:
The patent fundamentally changes the chemical structure parameter of the lubricant from saturated to polyunsaturated fatty acid salts. This parameter change eliminates the adverse health effects associated with traditional lubricants while preserving their functional performance in tablet manufacturing.
3Object-affected harmful factors
If polyunsaturated fatty acid salts are used as lubricants, then health safety is improved, but lubrication effectiveness may be reduced
Solution Approach 1:
The patent uses polyunsaturated fatty acid salts that are biologically compatible and safely eliminated from the body. These substances provide adequate lubrication for manufacturing purposes and then serve no harmful residual function, making them ideal for pharmaceutical applications where patient safety is paramount.
4Reliability
If magnesium stearate is used in higher concentrations, then lubrication is improved, but tablet strength is adversely affected
Solution Approach 1:
The patent changes the lubricant composition from magnesium stearate to polyunsaturated fatty acid salts, which do not exhibit the same strength-reducing effects at higher concentrations. This parameter change allows for effective lubrication without compromising tablet mechanical integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of polyunsaturated fatty acid salts provides superior tableting behavior with no significant delay in disintegration or dissolution, even at high concentrations, and reduces health risks associated with traditional lubricants.
Implementation Method 1
lubricants are essential ingredients in robust formulations to achieve this... lubrication is essential in order to reduce the friction between the surfaces of manufacturing equipment and that of organic solids
Implementation Method 2
In terms of powder flow, lubricants can improve the flowability of blends and aid unit operations
Data Source
AI summary
The present invention is related to a method of preparing a solid dosage form, comprising the steps of: a. preparing a lubricant consisting of at least one polyunsaturated fatty acid salt; b. adding the lubricant and ingredients for the solid dosage form to a mixer; c. optionally carrying out one or more of the following steps: granulation, drying and sizing, d. blending the contents of the mixer; and e. compressing or slugging the blended contents to produce a solid dosage form. Solid dosage forms prepared according to this method and the use of PUFA salts as lubricant in tableting applications for compression of solid components are further comprised by the present invention.